Table 5.

Cox regression analysis for predictors of TNFi discontinuation in patients with peripheral arthritis. Values are HR (95% CI).

			Final Model, Adjusted
Variables	Univariable	Multivariable Model, Adjusting for Baseline Variables Only	Baseline Variables and First-year DAS28 Remission	Baseline Variables and First-year EULAR Good Response	Baseline Variables and First-year ACR70 Response
Sex, male vs female	0.60 (0.47–0.76)^{^c}	0.63 (0.49–0.81)^{^c}			0.74 (0.52–1.06)^*
Age, per 10 yrs	0.90 (0.70–1.15)
Symptom duration, < vs ≥ 5 yrs	1.10 (0.86–1.41)
TNFi agent used, ETN vs other	1.53 (1.15–2.03)^{^b}	1.45 (1.09–1.93)^{^a}	1.92 (1.21–3.04)^{^b}	1.62 (1.05–2.50)^{^a}	1.65 (1.06–2.56)^{^a}
Clinical diagnosis
AS, ref	1.00 (ref)
PsA	1.06 (0.81–1.38)
Other	1.21 (0.84–1.73)
Year of TNFi therapy start, per 2 yrs	1.08 (1.00–1.17)^*
Previous csDMARD, yes vs no	0.95 (0.72–1.26)
MTX co-therapy, yes vs no	0.72 (0.56–0.92)^{^b}	0.65 (0.51–0.84)^{^b}		0.73 (0.50–1.05)^*	0.65 (0.46–0.93)^{^a}
Axial disease, yes vs no	0.97 (0.72–1.29)
CRP, > vs ≤ 1.2 mg/dl	0.74 (0.55–0.99)^{^a}	0.76 (0.57–1.02)^*
VAS global, > vs ≤ 60	1.28 (0.98–1.67)^*
PGA, > vs ≤ 2	1.00 (0.73–1.37)
SJC-28, > vs ≤ 2	1.26 (0.96–1.66)^**
TJC-28, > vs ≤ 3	1.32 (1.00–1.74)^{^a}	1.32 (1.00–1.75)^*	1.84 (1.10–3.06)^{^a}	1.82 (1.26–2.62)^{^b}	1.81 (1.26–2.59)^{^b}
DAS28 baseline, > vs ≤ 4.5	1.10 (0.84–1.46)		0.61 (0.36–1.03)^*
DAS28 remission, yes vs no	0.39 (0.29–0.55)^{^c}		0.35 (0.24–0.50)^{^c}
EULAR good response, yes vs no	0.42 (0.30–0.60)^{^c}			0.41 (0.29–0.58)^{^c}
ACR70, yes vs no	0.33 (0.19–0.60)^{^c}				0.29 (0.21–0.40)^{^c}

↵* p < 0.1.
↵** p < 0.2.
↵a p < 0.05.
↵b p < 0.01.
↵c p < 0.001. TNFi: tumor necrosis factor inhibitor; ETN: etanercept; AS: ankylosing spondylitis; PsA: psoriatic arthritis; csDMARD: conventional synthetic disease-modifying antirheumatic drugs; MTX: methotrexate; CRP: C-reactive protein; VAS: visual analog scale; PGA: physician’s global assessment; SJC-28: swollen joint count in 28 joints; TJC-28: tender joint count in 28 joints; DAS28: 28-joint Disease Activity Score; EULAR: European League Against Rheumatism; ACR70: American College of Rheumatology criteria 70% improvement.